<DOC>
	<DOCNO>NCT02695160</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability effect FIX antigen activity level ascend dos SB-FIX . SB-FIX intravenously deliver Zinc Finger Nuclease ( ZFN ) Therapeutic genome editing . It insert correct copy Factor 9 gene albumin locus hepatocytes goal lifelong therapeutic production Factor IX clot factor .</brief_summary>
	<brief_title>Ascending Dose Study Genome Editing Zinc Finger Nuclease Therapeutic SB-FIX Subjects With Severe Hemophilia B</brief_title>
	<detailed_description>The objective study provide long term expression Factor IX subject severe hemophilia B. SB-FIX therapeutic ZFN-mediated genome edit deliver adeno-associated virus ( AAV ) -derived vector . SB-FIX intended function placement corrective copy Factor IX transgene genome subject 's hepatocytes , control highly express endogenous albumin locus , expect provide permanent , liver-specific expression Factor IX lifetime hemophilia B subject .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Male &gt; 18 year age Severe hemophilia B ( native circulate FIX activity &lt; 1 % , without cross reactive material ) Presence neutralize antibody History hypersensitivity response allergic reaction FIX FIX product Currently receive long act FIX replacement therapy FIX mutation know associated FIX inhibitor Polymorphisms ZFN target region Presence liver mass MRI , elevate alphafetoprotein ( AFP ) Any contraindication use corticosteroid immunosuppression Currently receive antiviral therapy hepatitis B C history active hepatitis B hepatitis C HIV1 HIV1/2 antibody positive . Chronic anemia , leukopenia , thrombocytopenia Past medical history active tuberculosis significant fungal disease Symptomatic cardiovascular disease comorbid condition Markers hepatic inflammation overt occult cirrhosis History chronic renal disease creatinine â‰¥ 1.5 mg/dL Systemic ( iv oral ) immunomodulatory agent steroid use ( topical treatment allow ) History chronic infection chronic disorder consider unacceptable risk History malignancy except treat basal cell squamous cell carcinoma History alcohol substance abuse Previously receive gene therapy product Participation prior investigational drug medical device study within previous 3 month History therapeutic nonadherence Any reason , opinion Investigator Medical Monitor , would render subject unsuitable participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>